Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Antisoma (LSE:ASM) said data from 31 previously untreated non-small cell lung cancer (NSCLC) patients in an open-label
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury